VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Learn more about Galmed Pharmaceuticals Ltd's (GLMD) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
Financial Summary
Share Statistics
GLMD
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$3.5
$273.0
2%
Shares Out (Mil)
6.6
53.1
16%
Institutional Ownership
61.3%
92.4%
39%
Float (Mil)
6.4
40.1
14%
Beta
0.74
0.94
44%
Avg Daily Volume (000s)
38
496
25%
Price Change (52-week)
(64.2%)
57.5%
10%
Growth
GLMD
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
18.6%
(10.0%)
71%
EPS (5yr)
60.3%
16.0%
96
Dividends (5yr)
na
0.0%
na
Cash Flow (5yr)
71.2%
(15.6%)
97%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
na
na
na
Month Ago EPS
na
na
na
# Rev Up
na
na
na
# Rev Down
na
na
na
Three Months Ago EPS
na
na
na
Year/Year Chg
na
na
na
Financials
GLMD
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$37
na
Net Income (TTM) (Mil)
($11)
($43)
28%
EPS (TTM)
($2.016)
($1.500)
14%
Operating Cash Flow (TTM) (Mil)
($8)
($31)
22%
Net Cash Flow (TTM) (Mil)
na
$2
na
Long-Term Debt (Q1) (Mil)
$0
$4
0%
Enterprise Value (Q1) (Mil)
($12)
$166
2%
Valuation
GLMD
Industry Median
Percentile (All Stocks)
P/B
0.25
2.71
4%
P/E
na
18.9
na
Dividend Yield
na
0.0%
na
PEG (5yr hist)
na
0.9
na
Ratios
GLMD
Industry Median
Percentile (All Stocks)
Gross Margin
na
64.2%
na
Net Margin
na
(73.0%)
na
ROA
(64.0%)
(47.7%)
9%
ROE
(72.1%)
(55.1%)
12%
Liabilities to Assets
13.0%
29.8%
8%
F-Score
1
3
1%
Galmed Pharmaceuticals Ltd. did not pass any screens on 8/14/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors